ISRN PharmaceuticsPub Date : 2011-01-01Epub Date: 2011-07-12DOI: 10.5402/2011/521353
Karunanidhi S Lakshmi, Tirumala Rajesh
{"title":"Separation and quantification of eight antidiabetic drugs on a high-performance liquid chromatography: its application to human plasma assay.","authors":"Karunanidhi S Lakshmi, Tirumala Rajesh","doi":"10.5402/2011/521353","DOIUrl":"https://doi.org/10.5402/2011/521353","url":null,"abstract":"<p><p>An analytical method based on isocratic reverse phase high-performance liquid chromatography was developed and validated for the separation and quantification of eight antidiabetic drugs: rosiglitazone, pioglitazone, glipizide, gliclazide, repaglinide, nateglinide, glibenclamide, and glimepiride for their application in human plasma assay. Metformin is used as internal standard. Analysis was done on Onyx monolithic C(18) column (100 × 4.6 mm, i.d., 5 μm) using a mixture of 0.05% formic acid in water and methanol in the ratio of 42 : 58 (v/v) fixed at a flow rate of 0.5 mL/min, and they were monitored at 234 nm. Separation was achieved in less than 20 min. The calibration curves were linear in the range of 50-2000 ng/mL. The method was validated for its recovery, intra- and interday precision, stability, specificity, and selectivity. Plasma samples were prepared using solid-phase extraction of analytes. Hence, the developed method was found to be suitable for the routine analysis of selected antidiabetic drugs in biological matrices.</p>","PeriodicalId":14802,"journal":{"name":"ISRN Pharmaceutics","volume":"2011 ","pages":"521353"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5402/2011/521353","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30505770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ISRN PharmaceuticsPub Date : 2011-01-01Epub Date: 2011-07-20DOI: 10.5402/2011/805983
Irina Piatkov, Trudi Jones
{"title":"Pharmacogenetics and gender association with psychotic episodes on nortriptyline lower doses: patient cases.","authors":"Irina Piatkov, Trudi Jones","doi":"10.5402/2011/805983","DOIUrl":"https://doi.org/10.5402/2011/805983","url":null,"abstract":"<p><p>The variation in individual responses to psychotropic drug treatment remains a critical problem in the management of psychotic disorders. Although most patients will experience remission, some patients may develop drug-induced adverse effects that may range from troublesome to life threatening. Antidepressants are freely prescribed by general practitioners, and there should be constant awareness in the medical community about possible serious side effects. We describe two cases of adverse drug reactions on low dosage treatment that led to extreme psychotic episodes as examples of the potential for dangerous side effects. The patients developed adverse reactions on the normal recommended dosage of nortriptyline, a tricyclics antidepressant (TCA). Both were females, with no history of antidepressant treatment, unsocial behaviour, nor any family history of psychosis, but both experienced severe psychiatric symptoms. Pharmacogenetic tests can easily be performed and interpreted according to the likelihood of adverse reactions and should be included in toxicity interpretation.</p>","PeriodicalId":14802,"journal":{"name":"ISRN Pharmaceutics","volume":"2011 ","pages":"805983"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5402/2011/805983","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30506744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ISRN PharmaceuticsPub Date : 2011-01-01Epub Date: 2011-07-20DOI: 10.5402/2011/651909
Shailesh T Prajapati, Charmi G Patel, Chhagan N Patel
{"title":"Formulation and evaluation of transdermal patch of repaglinide.","authors":"Shailesh T Prajapati, Charmi G Patel, Chhagan N Patel","doi":"10.5402/2011/651909","DOIUrl":"10.5402/2011/651909","url":null,"abstract":"<p><p>Repaglinide has the half life of 1 hour, and bioavailability in the body is 56% due to first-pass metabolism. The total daily dose of Repaglinide is 16 mg (e.g., 4 mg four times daily depending on meal patterns); hence, it required frequent dosing. Transdermal patch of Repaglinide was prepared to sustain the release and improve bioavailability of drug and patient compliance. Different formulations were prepared by varying the grades of HPMC and concentration of PVP K30 by solvent casting method. The prepared formulations were evaluated for various parameters like thickness, tensile strength, folding endurance, % elongation, % moisture content, % moisture uptake, % drug content, in vitro drug release, in vitro permeation, and drug excipient compatibility. A 3(2) full factorial design was applied to check the effect of varying the grades of HPMC (X(1)) and PVP concentration (X(2)) on the responses, that is, tensile strength, percentage drug released in 1 hr (Q(1)), 9 hr (Q(9)), and diffusion coefficient as a dependent variables. In vitro release data were fitted to various models to ascertain kinetic of drug release. Regression analysis and analysis of variance were performed for dependent variables. The results of the F2 statistics between factorial design batches and theoretical profile were used to select optimized batch. Batch F6 was considered optimum batch which contained HPMC K100 and PVP (1.5%), showed release 92.343% up to 12 hr, and was more similar to the theoretical predicted dissolution profile (f(2) = 69.187).</p>","PeriodicalId":14802,"journal":{"name":"ISRN Pharmaceutics","volume":"2011 ","pages":"651909"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3263722/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30506741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ISRN PharmaceuticsPub Date : 2011-01-01Epub Date: 2011-07-28DOI: 10.5402/2011/276250
Dasharath M Patel, Divyesh K Patel, Chhagan N Patel
{"title":"Formulation and evaluation of floating oral in situ gelling system of amoxicillin.","authors":"Dasharath M Patel, Divyesh K Patel, Chhagan N Patel","doi":"10.5402/2011/276250","DOIUrl":"10.5402/2011/276250","url":null,"abstract":"<p><p>Purpose. Effective Helicobacter pylori eradication requires delivery of the antibiotic locally in the stomach. High dose of amoxicillin (750 to 1000 mg) is difficult to incorporate in floating tablets but can easily be given in liquid dosage form. Keeping the above facts in mind, we made an attempt to develop a new floating in situ gelling system of amoxicillin with increased residence time using sodium alginate as gelling polymer to eradicate H. pylori. Methods. Floating in situ gelling formulations were prepared using sodium alginate, calcium chloride, sodium citrate, hydroxypropyl methyl cellulose K100, and sodium bicarbonate. The prepared formulations were evaluated for solution viscosity, floating lag time, total floating time, and in vitro drug release. The formulation was optimized using a 3(2) full factorial design. Dissolution data were fitted to various models to ascertain kinetic of drug release. Regression analysis and analysis of variance were performed for dependent variables. Results. All formulations (F(1)-F(9)) showed floating within 30 s and had total floating time of more than 24 h. All the formulations showed good pourability. It was observed that concentration of sodium alginate and HPMC K100 had significant influence on floating lag time, cumulative percentage drug release in 6 h and 10 h. The batch F(8) was considered optimum since it showed more similarity in drug release (f(2) = 74.38) to the theoretical release profile. Conclusion. Floating in situ gelling system of amoxicillin can be formulated using sodium alginate as a gelling polymer to sustain the drug release for 10 to 12 h with zero-order release kinetics.</p>","PeriodicalId":14802,"journal":{"name":"ISRN Pharmaceutics","volume":"2011 ","pages":"276250"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5402/2011/276250","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30505768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
